NCT00290472 - CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

B-cell Chronic Lymphocytic LeukemiaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueMalignant NeoplasmNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaSplenic Marginal Zone LymphomaWaldenström Macroglobulinemia

Interventions

DRUG

temsirolimus

Trial Locations (13)

46601

Northern Indiana Cancer Research Consortium, South Bend

46845

Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne

49085

Oncology Care Associates PLLC, Saint Joseph

52242

University of Iowa, Iowa City

53226

Froedtert and the Medical College of Wisconsin, Milwaukee

60153

Loyola University Medical Center, Maywood

60201

Evanston Hospital CCOP, Evanston

60426

Ingalls Memorial Hospital, Harvey

60525

Adventist La Grange Memorial Hospital, La Grange

60637

University of Chicago, Chicago

60702

Central Illinois Hematology Oncology Center, Springfield

62526

Decatur Memorial Hospital, Decatur

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH